Sponsored by:

Nuclear Medicine: Page 325

Molecular Insight starts Trofex trial
By AuntMinnie.com staff writers
Molecular Insight Pharmaceuticals of Cambridge, MA, has begun a phase I clinical trial for its Trofex molecular imaging program for detecting and staging metastatic prostate cancer.
June 11, 2008
UCLA develops new PET probe to monitor immune system
By Wayne Forrest
Researchers at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have created a new probe for use with PET that shows promise in monitoring the human immune system and its response to new therapies.
June 11, 2008
2008 06 11 13 21 11 43 Uclapet Probe Crop
Neoprobe starts phase III trial
By AuntMinnie.com staff writers
Gamma camera probe developer Neoprobe has launched a phase III clinical trial for its Lymphoseek radiopharmaceutical agent.
June 8, 2008
IBA, Wilex ink licensing pact
By AuntMinnie.com staff writers
Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.
June 5, 2008
MDS to press AECL on Chalk River reactors
By AuntMinnie.com staff writers
The chief executive of Canadian healthcare company MDS wants the Canadian government and Atomic Energy of Canada (AECL) to reverse the decision to cancel the construction of two nuclear reactors dedicated to medical isotopes.
June 5, 2008
MDS rallies in Q2 results
By AuntMinnie.com staff writers
Despite the past year's reactor shutdown turmoil, Canadian healthcare company MDS and its radioisotope developer MDS Nordion of Kanata, Ontario, posted revenue increases for its second quarter 2008.
June 4, 2008
IsoRay authorizes stock repurchase plan
By AuntMinnie.com staff writers
Medical isotope developer IsoRay has authorized the repurchase of up to 1 million shares of the Richland, WA, company’s common stock.
June 2, 2008
IBA finalizes acquisition of CIS bio
By AuntMinnie.com staff writers
Belgian radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve has moved to finalize its purchase of CIS bio International.
May 29, 2008
Using coronary CTA first versus SPECT cuts costs
By Eric Barnes
SPECT myocardial perfusion imaging has long been the primary modality for evaluating coronary artery disease. But research based on payor data covering millions of patients found that initial evaluation with coronary CT angiography cut costs significantly over a year's time for patients without coronary artery disease and the patient cohort overall.
May 29, 2008
2008 05 22 15 22 11 706
Draxis completes sale to Jubilant
By AuntMinnie.com staff writers
Draxis Health has finalized its acquisition by Jubilant Organosys of Noida, India.
May 28, 2008
AMIC starts fluorine-18 production
By AuntMinnie.com staff writers
Medical isotope producer Advanced Medical Isotope (AMIC) has begun production of fluorine-18 from its facility in Kennewick, WA.
May 27, 2008
Draxis shareholders OK Jubilant acquisition
By AuntMinnie.com staff writers
Draxis Health shareholders approved the Montreal-based radiopharmaceutical developer's acquisition by Jubilant Organosys of Noida, India, for $255 million (U.S.) or $6 per share.
May 22, 2008
Previous Page
Page 325 of 440
Next Page